Previous 10 | Next 10 |
-- Data for Investigational Gene Therapy Treatment NBIb-1817 (VY-AADC) Presented at the MDS Virtual Congress 2020 -- NBIb-1817 Treatment Showed Sustained Improvement in Motor Function, Including Greater “On” Time without Troublesome Dyskinesia and Reduction in Unified ...
SAN DIEGO , Sept. 11, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from two post-hoc analyses of Phase III data, demonstrating that once-daily ONGENTYS ® (opicapone) capsules decreased "off" time and increased "on" time without tr...
SAN DIEGO , Sept. 8, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 18 th Annual Global Healthcare Conference at 1:30 p.m. ET on Monday, September 14, 2020 . Kevin Gorman , Chief Executive Officer, and Matt Abernethy , Chief Fi...
Neurocrine Biosciences (NASDAQ: NBIX ) will present new data as part of 30 abstracts accepted from its movement disorder programs for tardive dyskinesia (TD) and Parkinson's disease at the virtual scientific meetings, 2020 Psych Congress on September 10–13 and the MDS Virtual Cong...
SAN DIEGO , Sept. 3, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present new data as part of 30 abstracts accepted from its movement disorder programs for tardive dyskinesia and Parkinson's disease at the upcoming virtual scientific meetin...
SAN DIEGO , Sept. 2, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Citi 15 th Annual BioPharma Virtual Conference at 12:35 p.m. ET on Wednesday, September 9, 2020 . Kevin Gorman , Chief Executive Officer, will present at the conference. ...
The following slide deck was published by Neurocrine Biosciences, Inc. in conjunction with their 2020 Q2 earnings Read more ...
Image source: The Motley Fool. Neurocrine Biosciences Inc (NASDAQ: NBIX) Q2 2020 Earnings Call Aug 3, 2020 , 4:30 p.m. ET Operator Continue reading
Neurocrine Biosciences ( NBIX ) is establishing at least some reputation and track record for “underpromising and overdelivering”, with yet another quarter of better-than-expected sales for lead drug Ingrezza. Whether it adds much value to the share price is another story, thou...
Neurocrine Biosciences ' (NASDAQ: NBIX) 30% plunge earlier this year during the coronavirus-fueled market meltdown is practically all but forgotten now. The stock was up around 15% as of the market close on Monday. But Neurocrine's shares are now likely to go even higher. The biotech announc...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...